Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Drug Delivery Systems

Background:

• Nanodrugs show promise for disease treatment but face challenges in preparation and biocompatibility.
• Clinical translation of nanodrugs is hindered by complex manufacturing and potential toxicity.
• Effective drug delivery systems are crucial for improving therapeutic outcomes in oncology.

Purpose of the Study:

• To develop a low-toxicity, long-lasting nanodrug for bladder tumor treatment using a self-assembly strategy.
• To improve the encapsulation efficiency and bioavailability of insoluble erdafitinib.
• To enable real-time monitoring of therapeutic response in bladder tumors.

Main Methods:

• Utilized a self-assembly strategy to create nanodrugs from compatible raw materials.
• Encapsulated the insoluble drug erdafitinib, achieving a 43.7% encapsulation rate.
• Incorporated a fluorescent protein module for real-time monitoring capabilities.

Main Results:

• The developed nanodrug demonstrated robust therapeutic effects with reduced side effects.
• Achieved a significantly prolonged in vivo half-life (14.4 h) and increased bioavailability (8.0 μg/mL·h) compared to the non-formulated drug.
• The nanodrug facilitated real-time feedback on therapeutic response through its fluorescent module.

Conclusions:

• A versatile technique for creating low-toxicity, long-acting, multifunctional nanoformulations was established.
• The nanodrug offers a promising approach for the multidimensional therapy of malignant tumors.
• This self-assembly strategy enhances erdafitinib's clinical applicability for bladder cancer treatment.